Sensus Healthcare Inc (NASDAQ:SRTS) shares reached a new 52-week high during trading on Friday . The stock traded as high as $9.23 and last traded at $9.23, with a volume of 110085 shares trading hands. The stock had previously closed at $7.58.

Several research analysts recently commented on SRTS shares. Northland Securities downgraded Sensus Healthcare from a “market perform” rating to an “under perform” rating in a research note on Tuesday, January 29th. Craig Hallum started coverage on Sensus Healthcare in a research note on Tuesday, December 11th. They issued a “buy” rating and a $10.00 price objective for the company. ValuEngine downgraded Sensus Healthcare from a “buy” rating to a “hold” rating in a research note on Friday, December 21st. TheStreet raised Sensus Healthcare from a “d” rating to a “c” rating in a research note on Thursday, February 14th. Finally, Roth Capital reissued a “buy” rating on shares of Sensus Healthcare in a research note on Tuesday, February 19th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $10.89.

The firm has a market cap of $148.47 million, a PE ratio of -65.93 and a beta of -0.44.

Sensus Healthcare (NASDAQ:SRTS) last issued its earnings results on Thursday, February 14th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.03. The company had revenue of $8.08 million during the quarter, compared to analysts’ expectations of $7.33 million. Sensus Healthcare had a negative return on equity of 12.64% and a negative net margin of 7.65%. On average, equities research analysts anticipate that Sensus Healthcare Inc will post 0.02 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of SRTS. BlackRock Inc. purchased a new stake in Sensus Healthcare in the 2nd quarter valued at $164,000. AWM Investment Company Inc. grew its holdings in Sensus Healthcare by 34.6% in the 3rd quarter. AWM Investment Company Inc. now owns 661,938 shares of the company’s stock valued at $5,547,000 after buying an additional 170,000 shares in the last quarter. Stonepine Capital Management LLC purchased a new stake in Sensus Healthcare in the 3rd quarter valued at $317,000. Renaissance Technologies LLC grew its holdings in Sensus Healthcare by 75.0% in the 3rd quarter. Renaissance Technologies LLC now owns 48,100 shares of the company’s stock valued at $403,000 after buying an additional 20,612 shares in the last quarter. Finally, B. Riley Financial Inc. purchased a new stake in Sensus Healthcare in the 3rd quarter valued at $168,000. Institutional investors own 6.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://theolympiareport.com/2019/03/17/sensus-healthcare-srts-sets-new-52-week-high-at-9-23.html.

Sensus Healthcare Company Profile (NASDAQ:SRTS)

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Read More: What is a conference call?

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.